Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

NCT05601830 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped It did not reach the expected results of clinical trial

Conditions

Minimal Residual Disease

Interventions

DRUG: QN-030a
DRUG: Cyclophosphamid
DRUG: Fludarabine
DRUG: Cytarabine

Sponsor

Institute of Hematology & Blood Diseases Hospital, China